---
title: "辉瑞公布 XTANDI 针对特定类型前列腺癌的总生存期试验结果。"
description: "辉瑞公布 XTANDI 针对特定类型前列腺癌的总生存期试验结果。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/261752375.md"
published_at: "2025-10-19T08:19:01.000Z"
---

# 辉瑞公布 XTANDI 针对特定类型前列腺癌的总生存期试验结果。

辉瑞公布 XTANDI 针对特定类型前列腺癌的总生存期试验结果。

### Related Stocks

- [PFE.US - 辉瑞](https://longbridge.com/zh-CN/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pfizer Announces Positive Phase 2b Results for Investigational Obesity Drug PF-08653944 | Pfizer Inc. has announced positive results from the Phase 2b VESPER-3 clinical trial for its investigational obesity dru | [Link](https://longbridge.com/zh-CN/news/274647411.md) |
| What's Driving the Market Sentiment Around Pfizer? | Pfizer's PFE short interest as a percent of float has fallen 9.0% since its last report. According to exchange reported  | [Link](https://longbridge.com/zh-CN/news/258741671.md) |
| 09:07 ETNew Study in JNCCN Unlocks Important Information About How to Treat Recurring Prostate Cancer | A new study published in the February 2026 issue of JNCCN reveals that PSMA PET/CT scans can significantly aid in treati | [Link](https://longbridge.com/zh-CN/news/275329671.md) |
| Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25 | Oric Pharmaceuticals (NASDAQ:ORIC) outlined its 2025 milestones at the Guggenheim Biotech Conference, including plans to | [Link](https://longbridge.com/zh-CN/news/275985972.md) |
| Medicus Pharma Receives FDA Clearance to Proceed with Teverelix Phase 2b Study | Medicus Pharma Ltd. has received FDA clearance to initiate its Phase 2b study of Teverelix®, a long-acting GnRH antagoni | [Link](https://longbridge.com/zh-CN/news/275457908.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。